MicroRNA-217 alleviates development of non-small cell lung cancer by inhibiting AKT3 via PI3K pathway

被引:1
作者
Qi, Y. -J [1 ]
Zha, W. -J. [2 ]
Zhang, W. [3 ]
机构
[1] Nanjing Univ TCM, Affiliated Hosp, Jiangsu Prov Hosp TCM, Dept Resp Med, Nanjing, Jiangsu, Peoples R China
[2] Nanjing Med Univ, Affiliated Hosp 1, Dept Resp Med, Nanjing, Jiangsu, Peoples R China
[3] Nanjing Univ TCM, Affiliated Hosp, Jiangsu Prov Hosp TCM, Dept Oncol, Nanjing, Jiangsu, Peoples R China
关键词
MicroRNA-217; NSCLC; AKT3; PI3K pathway; TARGETING AKT3; COLORECTAL-CANCER; MIRNA EXPRESSION; GASTRIC-CANCER; BREAST-CANCER; PROLIFERATION; METASTASIS; PROGNOSIS; APOPTOSIS; MIR-145;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
OBJECTIVE: To explore the role of microRNA-217 in non-small cell lung cancer (NSCLC) and its underlying mechanism. PATIENTS AND METHODS: MicroRNA-217 expression in 48 NSCLC tissues and paracancerous tissues were detected by qRT-PCR (quantitative Real-time polymerase chain reaction). The relationship between microRNA-217 expression and prognosis of NSCLC patients was analyzed. Target gene of microRNA-217 was predicted by bioinformatics method and further verified by luciferase reporter gene assay. Cell proliferation, cell cycle and apoptosis were detected after altering microRNA-217 expression in NSCLC cells. The effect of microRNA-217 on regulating PI3K pathway was detected by Western blot. RESULTS: MicroRNA-217 was downregulated in NSCLC tissues than that of paracancerous tissues. Shorter overall survival (OS) was observed in NSCLC patients with lower expression of microRNA-217 than those with higher expression. Overexpressed microRNA-217 remarkably inhibited proliferation and cell cycle, whereas induced apoptosis of NSCLC cells. AKT3 was screened out to be the target gene of microRNA-217. Western blot results demonstrated that microRNA-217 upregulated AKT3 and PI3K pathway-related genes. CONCLUSIONS: Downregulated microRNA-217 promotes the occurrence and progression of NSCLC through upregulating AKT3 via PI3K pathway.
引用
收藏
页码:5972 / 5979
页数:8
相关论文
共 27 条
  • [1] miR-145 suppresses thyroid cancer growth and metastasis and targets AKT3
    Boufraqech, Myriem
    Zhang, Lisa
    Jain, Meenu
    Patel, Dhaval
    Ellis, Ryan
    Xiong, Yin
    He, Mei
    Nilubol, Naris
    Merino, Maria J.
    Kebebew, Electron
    [J]. ENDOCRINE-RELATED CANCER, 2014, 21 (04) : 517 - 531
  • [2] Targeting Akt3 Signaling in Triple-Negative Breast Cancer
    Chin, Y. Rebecca
    Yoshida, Taku
    Marusyk, Andriy
    Beck, Andrew H.
    Polyak, Kornelia
    Toker, Alex
    [J]. CANCER RESEARCH, 2014, 74 (03) : 964 - 973
  • [3] MicroRNAs in Cancer
    Di Leva, Gianpiero
    Garofalo, Michela
    Croce, Carlo M.
    [J]. ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 9, 2014, 9 : 287 - 314
  • [4] PI3K and AKT: Unfaithful Partners in Cancer
    Faes, Seraina
    Dormond, Olivier
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2015, 16 (09): : 21138 - 21152
  • [5] PI3K: Downstream AKTion blocks apoptosis
    Franke, TF
    Kaplan, DR
    Cantley, LC
    [J]. CELL, 1997, 88 (04) : 435 - 437
  • [6] Gold MR, 2000, IMMUNOL REV, V176, P47
  • [7] Akt signalling in health and disease
    Hers, Ingeborg
    Vincent, Emma E.
    Tavare, Jeremy M.
    [J]. CELLULAR SIGNALLING, 2011, 23 (10) : 1515 - 1527
  • [8] Kim J, 2014, ANTICANCER RES, V34, P2297
  • [9] MiRNA-29b suppresses tumor growth through simultaneously inhibiting angiogenesis and tumorigenesis by targeting Akt3
    Li, Yan
    Cai, Bolei
    Shen, Liangliang
    Dong, Yan
    Lu, Qun
    Sun, Shukai
    Liu, Shiyu
    Ma, Shufang
    Ma, Peter X.
    Chen, Jihua
    [J]. CANCER LETTERS, 2017, 397 : 111 - 119
  • [10] AKT3 promotes prostate cancer proliferation cells through regulation of Akt, B-Raf & TSC1/TSC2
    Lin, Hui-Ping
    Lin, Ching-Yu
    Huo, Chieh
    Jan, Yee-Jee
    Tseng, Jen-Chih
    Jiang, Shih Sheng
    Kuo, Ying-Yu
    Chen, Shyh-Chang
    Wang, Chih-Ting
    Chan, Tzu-Min
    Liou, Jun-Yang
    Wang, John
    Chang, Wun-Shaing Wayne
    Chang, Chung-Ho
    Kung, Hsing-Jien
    Chuu, Chih-Pin
    [J]. ONCOTARGET, 2015, 6 (29) : 27097 - 27112